卡培他滨联合长春瑞滨治疗晚期乳腺癌临床观察

Clinical observation of capecitabine combined with vinorelbine in the treatment of advanced breast cancer

目的:观察卡培他滨联合长春瑞滨对耐药的晚期乳腺癌的疗效及毒性。方法:34例耐药的晚期乳腺癌,均接受卡培他滨2500 mg/m2,分早晚两次餐后30分钟温开水送服,第1-14天,间隔7天;长春瑞滨25mg/m2加入生理盐水100ml中静脉滴注15分钟,第1、8天,21天为1周期,化疗4个周期。结果:34例患者中,CR5例(14.71%),PR15例(44.12%),SD 8例(23.51%),PD 6例(17.65%),有效率为58.82%,疾病控制率为82.35%。结论:卡培他滨联合长春瑞滨治疗耐药的晚期乳腺癌有较好的疗效,不良反应轻,患者可耐受。

Objective：To observe the efficiency and toxicity of capecitabine combined with vinorelbine in the treatment of advanced breast cancer. Method：Thirty - four patients were treated with capecitabine 2500 mg/m^2, dayl - 14 and vinorelbine 25mg/m^2 on day 1, day 8.1 cycle was 21 days,treated for 4 cycles. Resdts：5 of 34 assessable patients achieved complete response （CR）, 15 patients had partial response （PR） ,8 had stable disease （SD） ,6 had progressive disease （PD）. The respone rate was 58.82%. Conclusion： Capecitabine combined with vinorelbine was an effective regimen with tolerable toxicity in the treatment of advanced breast cancer.